All times are listed in CEST (Central European Summer Time)

Displaying One Session

View
Munich Hall Industry Satellite Symposium

Seagen - Treatment sequencing in HER2-positive metastatic breast cancer: from guidelines to clinical practice (ID 30)

Date
Wed, 04.05.2022
Time
13:00 - 14:00
Chairs
Session Type
Industry Satellite Symposium
Seagen - Treatment sequencing in HER2-positive metastatic breast cancer: from guidelines to clinical practice (ID 30)

Introduction (ID 366)

Lecture Time
13:00 - 13:00
Speakers
Authors
Session Name
Seagen - Treatment sequencing in HER2-positive metastatic breast cancer: from guidelines to clinical practice (ID 30)
Room
Munich Hall
Date
Wed, 04.05.2022
Time
13:00 - 14:00
Seagen - Treatment sequencing in HER2-positive metastatic breast cancer: from guidelines to clinical practice (ID 30)

Patient case study: how does treatment sequencing vary in local clinical practice across Europe for HER2-positive MBC? (ID 367)

Lecture Time
13:00 - 13:00
Speakers
Authors
Session Name
Seagen - Treatment sequencing in HER2-positive metastatic breast cancer: from guidelines to clinical practice (ID 30)
Room
Munich Hall
Date
Wed, 04.05.2022
Time
13:00 - 14:00
Seagen - Treatment sequencing in HER2-positive metastatic breast cancer: from guidelines to clinical practice (ID 30)

Patient case study: how does local clinical practice vary for patients with brain metastases? (ID 368)

Lecture Time
13:00 - 13:00
Speakers
Authors
Session Name
Seagen - Treatment sequencing in HER2-positive metastatic breast cancer: from guidelines to clinical practice (ID 30)
Room
Munich Hall
Date
Wed, 04.05.2022
Time
13:00 - 14:00
Seagen - Treatment sequencing in HER2-positive metastatic breast cancer: from guidelines to clinical practice (ID 30)

Which local factors influence treatment sequencing for HER2-positive MBC? (ID 370)

Lecture Time
13:00 - 13:05
Speakers
Authors
Session Name
Seagen - Treatment sequencing in HER2-positive metastatic breast cancer: from guidelines to clinical practice (ID 30)
Room
Munich Hall
Date
Wed, 04.05.2022
Time
13:00 - 14:00
Seagen - Treatment sequencing in HER2-positive metastatic breast cancer: from guidelines to clinical practice (ID 30)

Consistency of approach: how can we personalise and adapt treatment sequencing for patients with HER2-positive MBC? (ID 371)

Lecture Time
13:05 - 13:10
Speakers
Authors
Session Name
Seagen - Treatment sequencing in HER2-positive metastatic breast cancer: from guidelines to clinical practice (ID 30)
Room
Munich Hall
Date
Wed, 04.05.2022
Time
13:00 - 14:00
Seagen - Treatment sequencing in HER2-positive metastatic breast cancer: from guidelines to clinical practice (ID 30)

Q&A (ID 372)

Lecture Time
13:10 - 13:20
Speakers
Authors
Session Name
Seagen - Treatment sequencing in HER2-positive metastatic breast cancer: from guidelines to clinical practice (ID 30)
Room
Munich Hall
Date
Wed, 04.05.2022
Time
13:00 - 14:00
Seagen - Treatment sequencing in HER2-positive metastatic breast cancer: from guidelines to clinical practice (ID 30)

Summary and session close (ID 373)

Lecture Time
13:20 - 13:20
Speakers
Authors
Session Name
Seagen - Treatment sequencing in HER2-positive metastatic breast cancer: from guidelines to clinical practice (ID 30)
Room
Munich Hall
Date
Wed, 04.05.2022
Time
13:00 - 14:00